Clinical Trial: Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042

U.S., Oct. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07222878) titled 'Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042' on Oct. 13.

Brief Summary: A Single-center, Open-label, Single-dose, Three-period, Fixed Sequence Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules

Study Start Date: Sept. 29

Study Type: INTERVENTIONAL

Condition: Epilepsy Alzheimer Disease Epilepsy Intractable

Intervention: DRUG: NPT 2042 (Reference formula/Formulation 1)

In Period 1 Day 1, participants will receive Formulation 1 in a fasted state (Treatment A).

DRUG: NPT 20...